BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

171 related articles for article (PubMed ID: 29281872)

  • 21. Local Recurrence After Primary Proton Beam Therapy in Uveal Melanoma: Risk Factors, Retreatment Approaches, and Outcome.
    Seibel I; Cordini D; Rehak M; Hager A; Riechardt AI; Böker A; Heufelder J; Weber A; Gollrad J; Besserer A; Joussen AM
    Am J Ophthalmol; 2015 Oct; 160(4):628-36. PubMed ID: 26133249
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Maximizing local tumor control and survival after proton beam radiotherapy of uveal melanoma.
    Egger E; Schalenbourg A; Zografos L; Bercher L; Boehringer T; Chamot L; Goitein G
    Int J Radiat Oncol Biol Phys; 2001 Sep; 51(1):138-47. PubMed ID: 11516863
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Prognostic Value of BAP1 and Preferentially Expressed Antigen in Melanoma (PRAME) Immunohistochemistry in Uveal Melanomas.
    Han LM; Lee KW; Uludag G; Seider MI; Afshar AR; Bloomer MM; Pekmezci M
    Mod Pathol; 2023 Apr; 36(4):100081. PubMed ID: 36788079
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Neoadjuvant proton beam irradiation vs. adjuvant ruthenium brachytherapy in transscleral resection of uveal melanoma.
    Böker A; Pilger D; Cordini D; Seibel I; Riechardt AI; Joussen AM; Bechrakis NE
    Graefes Arch Clin Exp Ophthalmol; 2018 Sep; 256(9):1767-1775. PubMed ID: 29907945
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Tissue-specific significance of BAP1 gene mutation in prognostic prediction and molecular taxonomy among different types of cancer.
    Wang XY; Wang Z; Huang JB; Ren XD; Ye D; Zhu WW; Qin LX
    Tumour Biol; 2017 Jun; 39(6):1010428317699111. PubMed ID: 28618948
    [TBL] [Abstract][Full Text] [Related]  

  • 26. BAP1 deficiency causes loss of melanocytic cell identity in uveal melanoma.
    Matatall KA; Agapova OA; Onken MD; Worley LA; Bowcock AM; Harbour JW
    BMC Cancer; 2013 Aug; 13():371. PubMed ID: 23915344
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Prognosis of Mucosal, Uveal, Acral, Nonacral Cutaneous, and Unknown Primary Melanoma From the Time of First Metastasis.
    Kuk D; Shoushtari AN; Barker CA; Panageas KS; Munhoz RR; Momtaz P; Ariyan CE; Brady MS; Coit DG; Bogatch K; Callahan MK; Wolchok JD; Carvajal RD; Postow MA
    Oncologist; 2016 Jul; 21(7):848-54. PubMed ID: 27286787
    [TBL] [Abstract][Full Text] [Related]  

  • 28. BAP1 regulates cell cycle progression through E2F1 target genes and mediates transcriptional silencing via H2A monoubiquitination in uveal melanoma cells.
    Pan H; Jia R; Zhang L; Xu S; Wu Q; Song X; Zhang H; Ge S; Xu XL; Fan X
    Int J Biochem Cell Biol; 2015 Mar; 60():176-84. PubMed ID: 25582751
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Survival after proton-beam irradiation of uveal melanomas.
    Kodjikian L; Roy P; Rouberol F; Garweg JG; Chauvel P; Manon L; Jean-Louis B; Little RE; Sasco AJ; Grange JD
    Am J Ophthalmol; 2004 Jun; 137(6):1002-10. PubMed ID: 15183783
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Recurrence of posterior uveal melanoma after 60Co episcleral plaque therapy.
    Karlsson UL; Augsburger JJ; Shields JA; Markoe AM; Brady LW; Woodleigh R
    Ophthalmology; 1989 Mar; 96(3):382-8. PubMed ID: 2710530
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Loss of BAP1 expression is associated with an immunosuppressive microenvironment in uveal melanoma, with implications for immunotherapy development.
    Figueiredo CR; Kalirai H; Sacco JJ; Azevedo RA; Duckworth A; Slupsky JR; Coulson JM; Coupland SE
    J Pathol; 2020 Apr; 250(4):420-439. PubMed ID: 31960425
    [TBL] [Abstract][Full Text] [Related]  

  • 32. 20-year assessment of metastatic latency and subsequent time to death after proton therapy for uveal melanomas.
    Bellocq D; Roy P; Kodjikian L; Mathis T; Nguyen AM; Herault J; Rivoire M; Négrier S; Thariat J; Grange JD
    Melanoma Res; 2020 Jun; 30(3):272-278. PubMed ID: 30320630
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Loss of BAP1 expression in metastatic tumor tissue is an event of poor prognosis in patients with metastatic clear cell renal cell carcinoma.
    da Costa WH; Fares AF; Bezerra SM; Morini MA; de Toledo Benigno LA; Clavijo DA; Fornazieri L; Rocha MM; da Cunha IW; de Cassio Zequi S
    Urol Oncol; 2019 Jan; 37(1):78-85. PubMed ID: 30446457
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Survival in patients with presymptomatic diagnosis of metastatic uveal melanoma.
    Kim IK; Lane AM; Gragoudas ES
    Arch Ophthalmol; 2010 Jul; 128(7):871-5. PubMed ID: 20625048
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Comparing the Prognostic Value of BAP1 Mutation Pattern, Chromosome 3 Status, and BAP1 Immunohistochemistry in Uveal Melanoma.
    van de Nes JA; Nelles J; Kreis S; Metz CH; Hager T; Lohmann DR; Zeschnigk M
    Am J Surg Pathol; 2016 Jun; 40(6):796-805. PubMed ID: 27015033
    [TBL] [Abstract][Full Text] [Related]  

  • 36. BAP1 germline mutation in two first grade family members with uveal melanoma.
    Maerker DA; Zeschnigk M; Nelles J; Lohmann DR; Worm K; Bosserhoff AK; Krupar R; Jägle H
    Br J Ophthalmol; 2014 Feb; 98(2):224-7. PubMed ID: 24187051
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Uveal melanoma treated with iodine-125 episcleral plaque: an analysis of dose on disease control and visual outcomes.
    Perez BA; Mettu P; Vajzovic L; Rivera D; Alkaissi A; Steffey BA; Cai J; Stinnett S; Dutton JJ; Buckley EG; Halperin E; Marks LB; Mruthyunjaya P; Kirsch DG
    Int J Radiat Oncol Biol Phys; 2014 May; 89(1):127-36. PubMed ID: 24613808
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Eyelids metastases from uveal melanoma: clinical and histopathologic features of two cases and literature review.
    Martel A; Oberic A; Moulin A; Zografos L; Hamedani M
    Eye (Lond); 2019 May; 33(5):767-771. PubMed ID: 30560912
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Evaluation of HSP-27, BAP1, BRAF V600E, CCR7, and PD-L1 expression in uveal melanoma on enucleated eyes and metastatic liver tumors.
    Ağın A; Kiratli H; Guresci S; Babaoglu B; Karakaya J; Soylemezoglu F
    Int J Biol Markers; 2022 Jun; 37(2):200-209. PubMed ID: 35341390
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Local Failure After Episcleral Brachytherapy for Posterior Uveal Melanoma: Patterns, Risk Factors, and Management.
    Bellerive C; Aziz HA; Bena J; Wilkinson A; Suh JH; Plesec T; Singh AD
    Am J Ophthalmol; 2017 May; 177():9-16. PubMed ID: 28163118
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.